AAAAI Conference Daily

There is a lot to learn in the late-breaking science sessions and clinical news developments at this year’s American Heart Association (AHA) meeting, including novel approaches to cardiovascular disease risk reduction, updates on interventional management for patients with acute coronary syndromes, and much more. A sample of topics below:

  • The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF): Results in Nondiabetic Patients
  • Results from the ORION-10 Trial
  • The COLchicine Cardiovascular Outcomes Trial (COLCOT)
  • Results of the BETonMACE Trial
  • ISCHEMIA-CKD: Primary Results of Clinical Outcomes
  • REDUCE-IT Cost Effectiveness Analysis
  • REDUCE-IT USA: Results From the 3,146 Patients Randomized in the United States
  • Many Statin-Treated Person/Elevated Triglyceride at Risk of Atherosclerotic CVD

Day 1

Day 2

Day 3

Day 4

Day 5


Quick Links